Gilead Sciences (GILD) 92.27 $GILD
Final Glance: Biotechnology companies
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 05, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Gilead Sciences (GILD) Approaches New Upside Target of $93.51
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $91.60 today and has reached the first level of resistance at $92.50. Investors may be interested in a cross of the next upside pivot targets of $93.51 and $95.42.
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
PR Newswire - Mon Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, GILD, BLDP, GSK, and LLY.
Doctor Evidence Partnering with Healthcare Decision-Makers on Hepatitis C Evidence
PRWeb - Sun Aug 03, 5:30AM CDT
Doctor Evidence ("DRE"
, the Santa Monica, California-based healthcare information leader has responded to marketplace clamor related to the transformative innovations in Hepatitis C virus (HCV) treatments with a comprehensive comparative effectiveness database that allows healthcare decision-makers to quickly identify and synthesize available evidence in this evolving market. The DRE HCV Data Hub-currently being used by an increasing number of payers, provider groups, guideline developers and manufacturers--provides the body of published evidence around HCV screening, diagnosis and treatment in a universally transparent and accessible software-service model. The initial wave of engagements and questions across these stakeholders is facilitating evidence-based decisions regarding patient subgroup considerations, coverage decisions, treatment comparisons, and to inform evolving research and real-world evidence opportunities.
TAL Education, Team Health Join The IBD 50 Resistance
at Investor's Business Daily - Fri Aug 01, 6:08PM CDT
Leading stocks took their licks in the past week, with only a small clique of IBD 50 stocks posting weekly gains. Among those, China-based TAL Education (XRS) hauled in an 11% gain to end the week at a new high. That left the chain of tutoring...
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Shares of GILD Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 01, 9:45AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 27.17% as of today's recent price of $92.27.
Oregon Medicaid targets expensive hepatitis drug
By JONATHAN J. COOPER - AP - Thu Jul 31, 9:09PM CDT
WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Final Glance: Biotechnology companies
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 05, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Gilead Sciences (GILD) Approaches New Upside Target of $93.51
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $91.60 today and has reached the first level of resistance at $92.50. Investors may be interested in a cross of the next upside pivot targets of $93.51 and $95.42.
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
PR Newswire - Mon Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, GILD, BLDP, GSK, and LLY.
Doctor Evidence Partnering with Healthcare Decision-Makers on Hepatitis C Evidence
PRWeb - Sun Aug 03, 5:30AM CDT
Doctor Evidence ("DRE"
, the Santa Monica, California-based healthcare information leader has responded to marketplace clamor related to the transformative innovations in Hepatitis C virus (HCV) treatments with a comprehensive comparative effectiveness database that allows healthcare decision-makers to quickly identify and synthesize available evidence in this evolving market. The DRE HCV Data Hub-currently being used by an increasing number of payers, provider groups, guideline developers and manufacturers--provides the body of published evidence around HCV screening, diagnosis and treatment in a universally transparent and accessible software-service model. The initial wave of engagements and questions across these stakeholders is facilitating evidence-based decisions regarding patient subgroup considerations, coverage decisions, treatment comparisons, and to inform evolving research and real-world evidence opportunities. TAL Education, Team Health Join The IBD 50 Resistance
at Investor's Business Daily - Fri Aug 01, 6:08PM CDT
Leading stocks took their licks in the past week, with only a small clique of IBD 50 stocks posting weekly gains. Among those, China-based TAL Education (XRS) hauled in an 11% gain to end the week at a new high. That left the chain of tutoring...
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Shares of GILD Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 01, 9:45AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 27.17% as of today's recent price of $92.27.
Oregon Medicaid targets expensive hepatitis drug
By JONATHAN J. COOPER - AP - Thu Jul 31, 9:09PM CDT
WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
